Pitching accuracy rates of over 99% for multiple cancer screens, Thrive launches with $110 million
For more than 25 years the founders of Thrive Earlier Detection have been researching ways to improve the accuracy of liquid biopsy tests.
The fruits of that labor from Dr. Bert Vogelstein, Dr. Kenneth Kinzler and Dr. Nickolas Papadopoulos — all professors and researchers at Johns Hopkins University — is CancerSEEK, a liquid biopsy test that has demonstrated specificity of over 99% in a retrospective study published by Science.
By minimizing false positives in cancer screening tools and providing a test with proven accuracy, doctors can take treatment actions earlier, which can lead to better survival rates for cancer patients.
Now, with FDA approval for its tests for pancreatic and ovarian cancer and a new study underway with a large healthcare provider, CancerSEEK is being rolled out to market through Thrive Earlier Detection with the help of a new $110 million round of funding.
Thrive works by analyzing highly targeted sets of DNA and proteins in the blood to detect cancer.
“Over the past 30 years we have made great strides in understanding cancer. Combining this knowledge with the latest in molecular testing technologies, our founders have developed a simple and affordable blood test for the detection of many cancers
This post was originally published on this site